EpiThany to conduct Phase II breast cancer trial of cancer vaccine EP-101 plus Bavencio

EpiThany Inc. (Seattle, Wash.) will conduct a Phase II breast cancer trial evaluating its EP-101 to treat in combination with Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE). The company plans to begin the double-blind, placebo-controlled trial in 1Q18 to evaluate the safety and immunological efficacy of EP-101 plus standard-of-care and Bavencio in about 84 patients...